At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 18 enrolled
Drug / intervention
KHK7580drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Who Are Unable to Undergo Parathyroidectomy or Relapse After Parathyroidectomy
In Brief
A Phase 3 clinical trial evaluating KHK7580 for Parathyroid Carcinoma and Primary Hyperparathyroidism. Completed, enrolled 18 participants across 1 site.
Detailed Summary
To evaluate the efficacy of KHK7580 orally administered up to 24 weeks for hypercalcemia in patient with parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParathyroid Carcinoma, Primary Hyperparathyroidism
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartAug 2017
First PostedSep 2017
Primary CompletionApr 2019
TodayJul 2026
First PostedSep 12, 2017
Enrollment StartAug 30, 2017
Primary CompletionApr 9, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.8 years ago
Interventions
KHK7580drug
oral administration